FierceBiotechOriginal article
{"a":[{"_":"Vogenx joins the IPO queue to fund phase 2-stage metabolic drug","$":{"href":"/biotech/vogenx-joins-ipo-queue-fund-phase-2-stage-metabolic-drug","hreflang":"en"}}]}
IPO/OfferingPositive
AI Analysis
Summary
Vogenx announced plans to pursue an IPO on Nasdaq to fund development of its Phase 2-stage SGLT1 inhibitor for metabolic disease.
Clinical Trial Data
Phase
2
Importance:5/10
Sentiment:
0.30
IPOmetabolic diseaseSGLT1 inhibitorPhase 2
Related Companies
Read the original article
Published by FierceBiotech on July 16, 2026 5:20 AM